Mirati

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, February 29, 2024
Senior, Merck, Research, FDA, Food, Cancer, Pembrolizumab, AACR, Conference, Mirati, Science, Therapy, Food and Drug Administration, Merck & Co., Patient, Pharming, Clinical trial, Mutation, Workforce, Pharmaceutical industry

Promoted Michael Carulli to Chief Financial Officer and appointed Masha Poyurovsky, Ph.D., as Vice President of Biology.

Key Points: 
  • Promoted Michael Carulli to Chief Financial Officer and appointed Masha Poyurovsky, Ph.D., as Vice President of Biology.
  • As of December 31, 2023, PMV Pharma had $228.6 million in cash, cash equivalents, and marketable securities, compared to $243.5 million at December 31, 2022.
  • Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.
  • KEYTRUDA (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
NSCLC, Leukemia, Research, AML, Pedal, QT interval, FTI, Mirati Therapeutics, Investment, Postcholecystectomy syndrome, Physician, Clinical trial, ID, HRAS, Mirati, Prognosis, Renal cell carcinoma, FLT3, Webcast, Patient, KURA, Disease, G&A, LDAC, HNSCC, Cancer, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a corporate update.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $32.5 million, compared to $22.7 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $14.2 million, compared to $12.5 million for the fourth quarter of 2022.
  • ET / 1:30 p.m. PT today, February 27, 2024, to discuss the financial results for the fourth quarter and full year 2023 and to provide a corporate update.

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Mental Health, Health, Infectious Diseases, Neurology, Pharmaceutical, Biotechnology, NSCLC, TED, Blood pressure, Cervical cancer, Psoriasis, Cetuximab, Infection, New Drug Application, SCLC, MAA, National Medical Products Administration, PMA, CIDP, NTRK, FDA, Nivolumab, Food, GEJ, Shanda, Schizophrenia, PDUFA, CRC, Bristol Myers Squibb, BMS, ADP, Safety, Mirati, TPS, Disease, HKT, Patient, Clinical trial, METIS, Fusion, Pancreatic cancer, NDA, NMPA, Pharmaceutical industry

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

Corcept Appoints Roberto Vieira as President, Oncology

Retrieved on: 
Monday, January 29, 2024
Senior, Bristol Myers Squibb, Neoplasm, Oncology, Mirati, Lung cancer, Ovarian cancer, Marketing, Pharmaceutical industry

Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month.

Key Points: 
  • Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month.
  • Mr. Vieira previously spent 15 years at Bristol-Myers Squibb in positions of increasing seniority, including Vice President of Worldwide Oncology Strategy.
  • “We are thrilled to welcome Roberto to the Corcept team,” said Dr. Belanoff.
  • I'm committed to building a strong oncology organization and launching first-in-class products that make a real impact in patients' lives," said Mr. Vieira.

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Retrieved on: 
Wednesday, January 10, 2024
Patient, European, CHMP, Therapy, MD, SAN, Partnership, Civil service commission, European Commission, Cancer, Lung cancer, NSCLC, RECIST, Mirati Therapeutics, Mirati, Doctor of Philosophy, Committee, Physician, Pharmaceutical industry

"KRAZATI offers an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C -mutated NSCLC and this approval expands the potential treatment options available," Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Germany.

Key Points: 
  • "KRAZATI offers an efficacious and tolerable therapeutic option for patients living with advanced KRASG12C -mutated NSCLC and this approval expands the potential treatment options available," Martin Reck, MD, PhD, Lung Clinic Grosshansdorf, Germany.
  • "With it's differentiated profile, KRAZATI offers an impactful treatment option for patients living with lung cancer.
  • This authorization follows the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in November 2023.
  • Mirati thanks the patients, physicians, investigators and site coordinators who participated in the clinical trials that led to this important approval.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, GAN

Retrieved on: 
Thursday, November 9, 2023
Bristol Myers Squibb, Sale, NSCLC, Fraud, Contingent value rights, Therapy, GAN, Advertising, Patient, Mirati Therapeutics, U.S. FDA, Security (finance), Mirati

If you are a Mirati shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Mirati shareholder, click here to learn more about your rights and options .
  • If you are a GAN shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Retrieved on: 
Wednesday, November 8, 2023
Class Action Lawsuit, Professional Services, Legal, BMY, Sale, NSCLC, NYSE, Contingent value rights, KSF, Bristol Myers Squibb, U.S. FDA, Patient, Pharmaceutical industry, Mirati

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, SP, MRTX

Retrieved on: 
Saturday, November 4, 2023
Standard BioTools, Bristol Myers Squibb, Sale, NSCLC, SomaLogic, Fraud, Contingent value rights, Advertising, SP Plus Corporation, U.S. FDA, Patient, Mirati Therapeutics, Security (finance), Mirati

If you are a SomaLogic shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a SomaLogic shareholder, click here to learn more about your rights and options .
  • If you are a SP® Plus shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Kura Oncology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
CR, Research, Mirati Therapeutics, NSCLC, AACR, Kura, Acute myeloid leukemia, FTI, Hematology, Mirati, Conference, KMT2A, CRH, KRAS, Azacitidine, HRAS, HNSCC, Disease, ID, Marketing, Webcast, Cancer, KURA, Oncology, Venetoclax, Mixed-phenotype acute leukemia, FLT3, Safety, European Society of Gynaecological Oncology, Renal cell carcinoma, Investment, Patient, Therapy, AML, Pharmaceutical industry, Bank, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the third quarter of 2023 were $29.3 million, compared to $25.0 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $13.1 million, compared to $11.6 million for the third quarter of 2022.
  • ET / 1:30 p.m. PT today, November 2, 2023, to discuss the financial results for the third quarter 2023 and to provide a corporate update.

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Retrieved on: 
Thursday, November 2, 2023
Mirati, NSCLC, Cancer, Patient, Mirati Therapeutics, Trial of the century, KURA, SAN, FTI, Pharmaceutical industry

“Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.

Key Points: 
  • “Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both duration and depth of antitumor response in preclinical models of KRASG12C-mutated NSCLC,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Preclinical work demonstrates the ability of adagrasib, in combination with a FTI, to improve patient outcomes,” said Alan Sandler, M.D., Chief Medical Officer, Mirati Therapeutics.
  • “This collaboration exemplifies the potential combinability of adagrasib as a key differentiation from other KRASG12C inhibitors.”
    Under the terms of the agreement, Kura will sponsor the Phase 1 study of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC.
  • Mirati will supply Kura with adagrasib for the study.